EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cross-reactivity of rPvs48/45, a recombinant Plasmodium vivax protein, with plasma from Plasmodium falciparum endemic areas of Africa

Saidou Balam iD, Kazutoyo Miura iD, Imen Ayadi, Drissa Konaté, Nathan C Incandela, Valentina Agnolon, Merepen A Guindo, Seidina A S Diakité, Sope Olugbile, Issa Nebie, Sonia M Herrera, Carole Long und 5 weitere

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0302605 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Saidou Balam und 16 weiteren Autor:innen. Beteiligte Einrichtung: Mali International Center for Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali. Hauptthemen laut MEDLINE: Plasmodium falciparum, Malaria, Falciparum, Plasmodium vivax, Protozoan Proteins. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH/NIAID.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ps 48/45, a Plasmodium gametocyte surface protein, is a promising candidate for malaria transmission-blocking (TB) vaccine. Due to its relevance for a multispecies vaccine, we explored the cross-reactivity and TB activity of a recombinant P. vivax Ps 48/45 protein (r Pvs 48/45) with plasma from P. falciparum -exposed African donors. Methods r Pvs 48/45 was produced in Chinese hamster ovary cell lines and tested by ELISA for cross-reactivity with plasma from Burkina Faso, Tanzania, Mali, and Nigeria. In addition, BALB/c mice were immunized with the r Pvs 48/45 protein formulated in Montanide ISA-51 and inoculated with a crude extract of P. falciparum NF-54 gametocytes to evaluate the parasite-boosting effect on r Pvs 48/45 antibody titers. Specific anti-r Pvs 48/45 IgG purified from African plasma was used to evaluate the ex vivo TB activity on P. falciparum, using standard mosquito membrane feeding assays (SMFA). Results r Pvs 48/45 protein showed cross-reactivity with plasma of individuals from all four African countries, in proportions ranging from 94% (Tanzania) to 40% (Nigeria). Also, the level of cross-reactive antibodies varied significantly between countries (p < 0.0001), with a higher antibody level in Mali and the lowest in Nigeria. In addition, antibody levels were higher in adults ( ≥ 17 years) than young children ( ≤ 5 years) in both Mali and Tanzania, with a higher proportion of responders in adults (90%) than in children (61%) (p < 0.0001) in Mali, where male (75%) and female (80%) displayed similar antibody responses. Furthermore, immunization of mice with P. falciparum gametocytes boosted anti- Pvs 48/45 antibody responses, recognizing P. falciparum gametocytes in indirect immunofluorescence antibody test. Notably, r Pvs 48/45 affinity-purified African IgG exhibited a TB activity of 61% against P. falciparum in SMFA.

Conclusion

Plasma from African volunteers predominantly exposed to P. falciparum cross-recognized the r Pvs 48/45 protein. This, together with the functional activity of IgG, warrants further studies for the potential development of a P. vivax and P. falciparum cross-protective TB vaccine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plasmodium falciparumMalaria, FalciparumPlasmodium vivaxProtozoan ProteinsAntigens, ProtozoanAnimalsCross ReactionsHumansMiceRecombinant ProteinsFemaleMice, Inbred BALB CAntibodies, ProtozoanCricetulusAdultAfricaMalaria VaccinesCHO CellsAdolescentMaleMaliImmunoglobulin GMalaria, Vivax

Substanzen

Recombinant ProteinsProtozoan ProteinsAntibodies, ProtozoanMalaria VaccinesAntigens, ProtozoanImmunoglobulin G

Autor:innen und Institutionen

  • Mali International Center for Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
  • Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America.
  • Immunobiology Department, University of Lausanne, Lausanne, Switzerland.
  • Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  • Groupe de Recherche Action Santé, Burkina Faso, West Africa.
  • Caucaseco Scientific Research Center, Cali, Colombia.

ORCID-Profile: Saidou Balam, Kazutoyo Miura, Myriam Arevalo Herrera

Förderung

  • NIAID NIH HHS
  • NIH/NIAID

Zitieren

APA

Balam, S., Miura, K., Ayadi, I., Konaté, D., Incandela, N. C., Agnolon, V., Guindo, M. A., Diakité, S. A. S., Olugbile, S., Nebie, I., Herrera, S. M., Long, C., Kajava, A. V., Diakité, M., Corradin, G., Herrera, S., & Herrera, M. A. (2025). Cross-reactivity of rPvs48/45, a recombinant Plasmodium vivax protein, with plasma from Plasmodium falciparum endemic areas of Africa. PLOS ONE. https://doi.org/10.1371/journal.pone.0302605

Vancouver

Balam S, Miura K, Ayadi I, Konaté D, Incandela NC, Agnolon V, et al. Cross-reactivity of rPvs48/45, a recombinant Plasmodium vivax protein, with plasma from Plasmodium falciparum endemic areas of Africa. PLOS ONE. 2025. doi:10.1371/journal.pone.0302605

BibTeX
@article{Balam2025,
  author = {Balam, Saidou and Miura, Kazutoyo and Ayadi, Imen and Konaté, Drissa and Incandela, Nathan C and Agnolon, Valentina and Guindo, Merepen A and Diakité, Seidina A S and Olugbile, Sope and Nebie, Issa and Herrera, Sonia M and Long, Carole and Kajava, Andrey V and Diakité, Mahamadou and Corradin, Giampietro and Herrera, Socrates and Herrera, Myriam Arevalo},
  title = {Cross-reactivity of rPvs48/45, a recombinant Plasmodium vivax protein, with plasma from Plasmodium falciparum endemic areas of Africa},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0302605}
}
Kostenlos starten →